MAP - Market Access Podcast
av Dr. Stefan Walzer
How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng?
Om denne podkasten
Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.
MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.
The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.
Episoder
De 20 nyeste av 123 episoder
- How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng? · 39 min · Sesong 1 Episode 123AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate…
- Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture? · 45 min · Sesong 1 Episode 122When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with…
- What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann? · 42 min · Sesong 1 Episode 121In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether…
- How Do You Build a High-Performing Team in Pharma, Dr. Maurice Kléber? · 39 min · Sesong 1 Episode 120In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes — drawing on 18 years…
- Where Does AI Really Add Value in Market Access, Dr. Seye Abogunrin? · 38 min · Sesong 1 Episode 119Everyone wants AI to click the button for them — the real question is whether you still need to click it at all. In this episode of MAP – the Market Access Podcast, Dr. Stefan…
- Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier? · 29 min · Sesong 1 Episode 118By the time most health economists get pulled in, the recipe is already set. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with two industry…
- How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost) · 35 min · Sesong 1 Episode 117This is a repost of a popular episode of MAP - Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam…
- How Did MFN Turn Swiss Pricing into an Industrial Policy Problem, Dr. Marcel Boller? · 33 min · Sesong 1 Episode 116When Bern sets a price, Washington now listens. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Marcel Boller, Pharma and Medtech Expert…
- Is the EU "Launch Obligation" Really as Scary as It Sounds, Dr. Alexander Natz? · 32 min · Sesong 1 Episode 115In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory…
- Dynamic Rebates, Drug Tenders & AMNOG: Is Germany Rewriting the Rules for Pharma, Thomas Hammerschmidt? · 38 min · Sesong 1 Episode 114Tune in to the newest episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer engages in an insightful discussion with Prof. Dr. Thomas Hammerschmidt, a leading expert…
- Wie finanziert Deutschland Gesundheitsinnovation, ohne den Patientenzugang zu gefährden, Afschin Gandjour? · 36 min · Sesong 1 Episode 113In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über…
- What lessons can Market Access teams learn from an Olympic medalist, Livia Altmann? · 39 min · Sesong 1 Episode 112From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan…
- How Are UK NICE and US IRA/MFN Rewriting Global Pharma Pricing, Sreeram Ramagopalan? · 31 min · Sesong 1 Episode 111In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world…
- How Can Europe Move from Innovation Paradox to Powerhouse, Cuno Moser? · 39 min · Sesong 1 Episode 110In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe's "innovation paradox" in…
- Are primary research platforms adapting to payer dynamics, Shrutya Bhalla? · 39 min · Sesong 1 Episode 109In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era…
- How Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton? · 41 min · Sesong 1 Episode 108In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and Development Partnership, about how…
- Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel? · 35 min · Sesong 1 Episode 107In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former…
- From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher? · 40 min · Sesong 1 Episode 106In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore…
- Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali? · 53 min · Sesong 1 Episode 105In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds…
- What Makes Australia’s HTA Approach to Equity and Health Productivity Unique, Zanfina Ademi? · 43 min · Sesong 1 Episode 104In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare…







